Pharmaceutical monopolies and KRAS-targeted therapies: How patented drug development exploits systemic inequities in lung cancer treatment access
Original framing: “STAT+: Roche gets a lung cancer win with its KRAS drug divarasib” — STAT News
Marginalized voices—such as those of lung cancer survivors in Nigeria, where 90% of cases are diagnosed at late stages due to lack of screening—highlight the absurdity of framing divarasib as a 'win' when it remains inaccessible. In South Africa, the *Treatment Action Campaign* has long criticized pharmaceutical monopolies for pricing drugs like efavirenz (for HIV) at levels that strain public healthcare budgets. Similarly, Indigenous cancer survivors in Canada have criticized the lack of culturally safe care in KRAS trials, where protocols ignore traditional healing practices. The absence of these voices in the ESMO presentation reinforces the myth of 'universal' medical progress, masking the reality of health apartheid. Their testimonies reveal that KRAS therapies are not a panacea but a symptom of a broken system.
The sensationalized framing of Roche’s KRAS drug divarasib as a medical breakthrough obscures the deeper systemic crisis of how pharmaceutical capitalism exploits lung cancer disparities.
KRAS mutations, while biologically targeted, are socially constructed through tobacco industry influence, environmental pollution, and historical exclusion of marginalized populations from clinical trials—a legacy that persists in the current trial designs. Indigenous and cross-cultural perspectives reveal that lung health is not merely a genetic or biochemical issue but a reflection of broader ecological and cultural equilibria, from the *prana* in Ayurveda to the *kaupapa Māori* in New Zealand. The trickster irony here is that the 'win' of divarasib is predicated on the failure of public health policies to address smoking, pollution, and inequitable access to care. Solutions must therefore move beyond individual drugs to systemic interventions: patent pools to ensure affordability, Indigenous-led trials to restore ethical trust, tobacco industry reparations to address historical harms, and bundled environmental-lifestyle co-interventions to tackle root causes. Without these, divarasib remains a Band-Aid on a systemic wound—one that perpetuates the very inequities it claims to cure.